Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868507 | 0.89 | DRD2 (0.45) | DRD2HTR2AHTR1AHTR7HRH1 | |
| SCHEMBL4878093 | 0.89 | DRD2 (0.47) | DRD2HTR2AHTR1AHTR7HRH1 | |
| SCHEMBL4877174 | 0.82 | HTR1A (0.51) | HTR1A | |
| SCHEMBL7118802 | 0.78 | CYP1A2 (0.47) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL7120297 | 0.77 | KDM4E (0.40) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL4874631 | 0.77 | DRD2 (0.42) | DRD2HTR2AHTR1AHTR7HRH1 | |
| SCHEMBL4876727 | 0.74 | DRD2 (0.40) | DRD2HTR2AHTR1AHTR7HRH1 | |
| SCHEMBL4868382 | 0.74 | DRD2 (0.42) | DRD2HTR2AHRH1HRH3DRD3 | |
| SCHEMBL7120408 | 0.74 | HTR1A (0.46) | DRD2HTR2AHTR1AHTR7DRD3 | |
| SCHEMBL7130688 | 0.74 | HTR2A (0.41) | DRD2HTR2AHTR1AHTR7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | claimed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | claimed |
| EP-1399438-B1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2005-12-07 | — | — | EP | claimed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | claimed |
| US-7393845-B2 | Heteroaryl derivates, their preparation and use | H. LUNDBECK A/S (DK) | 2008-07-01 | — | — | US | disclosed |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
| EP-1399438-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002556-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | DRD2 20/4885HTR2A 41/4885HTR1A 3/4885 |
| US-20080027071-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR2C | DRD2 23/4885HTR2A 34/4885HTR1A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.